Switched to lanreotide Autogel
17 events/32 patients
median, 14.0 months [95% CI: 10.1, NC]
Time to progression (TTP) in placebo patients with
progressive disease (PD)
(32 patients with PD starting on lanreotide: PBO-LAN group)
CLARINET STUDY: LANREOTIDE IS EFFECTIVE
IN PROGRESSIVE ENTEROPANCREATIC NET
Caplin M, et al.
Endocr Relat Cancer
2016
100
0
0
6
12
18
24
30
36
42
48
54
Time From Centrally Assessed PD in Core Study, months
90
80
70
60
50
40
30
20
10
Patients Alive and With No Progression, %
